Ashfield Capital Partners LLC decreased its stake in Amgen (NASDAQ:AMGN) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 59,514 shares of the medical research company’s stock after selling 1,635 shares during the period. Amgen accounts for 1.3% of Ashfield Capital Partners LLC’s portfolio, making the stock its 17th largest position. Ashfield Capital Partners LLC’s holdings in Amgen were worth $10,349,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Toronto Dominion Bank raised its stake in Amgen by 11.0% during the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock valued at $52,066,000 after acquiring an additional 27,726 shares in the last quarter. Teacher Retirement System of Texas increased its position in shares of Amgen by 16.5% during the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock valued at $138,115,000 after purchasing an additional 104,871 shares during the period. Putnam FL Investment Management Co. acquired a new position in shares of Amgen during the 3rd quarter valued at $447,000. Moody Lynn & Lieberson LLC acquired a new position in shares of Amgen during the 3rd quarter valued at $2,353,000. Finally, Patten Group Inc. increased its position in shares of Amgen by 1,151.5% during the 3rd quarter. Patten Group Inc. now owns 27,859 shares of the medical research company’s stock valued at $389,000 after purchasing an additional 25,633 shares during the period. 79.55% of the stock is currently owned by institutional investors and hedge funds.
AMGN has been the topic of several research analyst reports. Vetr cut Amgen from a “buy” rating to a “hold” rating and set a $184.25 price target on the stock. in a research report on Wednesday, January 3rd. Royal Bank of Canada reiterated a “hold” rating and set a $189.00 price target on shares of Amgen in a research report on Wednesday, January 24th. Barclays lowered their price target on Amgen from $190.00 to $180.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 5th. ValuEngine cut Amgen from a “buy” rating to a “hold” rating in a research report on Monday, April 2nd. Finally, Piper Jaffray reiterated a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $190.57.
Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.89 earnings per share. research analysts expect that Amgen will post 13.24 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be given a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 annualized dividend and a dividend yield of 3.08%. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
Amgen announced that its Board of Directors has approved a stock buyback program on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 4,575 shares of company stock valued at $838,064. 0.19% of the stock is currently owned by insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.